Measurement of cell kinetics in cervical tumours using bromodeoxyuridine
| Autor: | TG Cooke, P.D. Stanton, AB MacLean, R.P. Symonds, BS Bolger |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Cancer Research Pathology medicine.medical_specialty Tumour heterogeneity Biopsy medicine.medical_treatment Broxuridine Uterine Cervical Neoplasms Biology S Phase chemistry.chemical_compound medicine Carcinoma Humans Doubling time Neoplasm Staging Ploidies Epithelioma medicine.diagnostic_test Cell Cycle Age Factors DNA Neoplasm Middle Aged Flow Cytometry medicine.disease Radiation therapy Kinetics Bromodeoxyuridine Oncology chemistry Lymphatic Metastasis Female Research Article |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.1993.307 |
| Popis: | The pre-treatment cell kinetics of 120 cervical tumours were assessed following the in vivo labelling with the thymidine analogue Bromodeoxyuridine (BrdUrd). In 89% both static and temporal kinetic parameters could be measured. Through the analysis of multiple biopsies from each tumour marked intra tumour heterogeneity was demonstrated. The median values for the most highly labelled sample analysed for each tumour were; S-phase duration (Ts) 12.1 h, BrdUrd labelling index (CLI) 9.5% and potential tumour doubling time 4.4 days. There was a significant elevation in CLI, but no difference in Ts, between tumour and non-neoplastic cervical tissue. There was a significant elevation in CLI, advanced stage and large size tumours. Although a significant elevation in CLI was found in aneuploid tumours this is likely to represent the systemic bias of the calculation methods, with no difference being seen between aneuploid and diploid tumours when BrdUrd labelling was measured with-out reference to the nuclei DNA content. The majority of these patients were treated with radiotherapy and cell kinetic data will be correlated with treatment response when adequate follow up has been achieved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|